1Liaw YF, Leung NW, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B[J]. Liver Int,2005,25(3) :472-489.
2Nishida T, Kobashi H, Fujio S, et al. A prospective and comparative cohort study on efficiency and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis[J]. Gastroenterol Hepatol, 2008,23 (5) : 794-803.
5Ding X, Massashi M, Yao GB, et al. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai China. Intervirology,2001,44 : 43 -47.
6Ding R, Ool E. Durability of HBeAg responses to lamivudine in Asian Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol, 2002,17(Suppl) : A120.
7Liaw YF,Leung NW, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B. Liver Int,2005,25:472-489.
8Yao GB,Cui ZY, Wang BE, et al. Efficacy of 5 years of lamivudine in Chinese patients with chronic hepatitis B. Proe. 11th International Symposium on Viral Hepatitis and Liver Disease. 2003.
9Dienstag JL, Cianeiara J, Karayalein S, et al. Durability of serologic response after lamivudine treatment of ehronie hepatitis B. Hepatology, 2003,37 : 748-755.
10Lee KM,Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepatitis, 2002,9 : 208-212.
